Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study seeks new treatments for oral cancer in dogs
The team aims to identify the biological markers that show whether the cancer is likely to spread.

Findings could lead to better outcomes for canine patients.

Vets at the University of Edinburgh are seeking new treatments for canine oral malignant melanoma.

One of the most common types of mouth cancer affecting dogs, it hoped the identification of new drugs could enhance the outcome for patients diagnosed with this devastating disease.

Building on previous research, the study will see scientists from the University’s Hospital for Small Animals, the Roslin Institute and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, study cancerous tissue samples from laboratories from across the globe. 

The team will identify the biological markers that show whether the cancer is likely to spread and grow tissue samples from diseased cells in the laboratory from which to test new treatments.

Dr Kelly Blacklock, a senior lecturer in small animal soft tissue surgery, said: “There is much to discover about the development of canine oral melanoma, for example how it may differ between breeds, its impact on various tissues or location within the mouth. 

“Identifying sub-types of this disease can help to inform our understanding how spread progresses, so that more effective potential drug targets, tailored to a sub-type, if necessary, can be identified.”

Funded by the Kennel Club Charitable Trust, scientists hope the study will make way for more personalised, precision canine medicine.The team also hopes to build a living biobank of organoids derived from dog tissue as a platform for screening drugs to prevent cancer spread. 

Reverend Bill King, chairman of The Kennel Club Charitable Trust, said: “We are proud to be supporting this important research, which could change lives of thousands of dogs in the future. More personalised medicine can bring better results, helping to stop the spread and save canine lives. 

“It is important more is invested in research like this to better understand canine diseases and give us better tools to fight them, and I am looking forward to learning about the findings of this research.”

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'